CNS-101 / Coyote Pharma - LARVOL DELTA

NEUROPSYCHOLOGICAL PHENOTYPING OF ALZHEIMER'S DEMENTIA AT HOME, USING THE CUMULUS NEULOGIQ PLATFORM WITH PLASMA BIOMARKERS (ADPD 2025) - "CNS101 was a year -long study desig ned with a consortium of 10 pharma companies, aiming to test the feasibility and evidential power of the NeuLogiq home -based platform to frequently and objectively sample cognitive function and neurophysiology... Real-world frequent sampling of behaviour and neurophysiology in AD is feasible. Fuller results on association between markers of pathology and other endpoints will be ready for presentation in April."

Biomarker • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation • GFAP

Biomarkers. (PubMed, Alzheimers Dement) - "Patients using digital technology autonomously in the home can yield data that matches the discriminative power of a traditional clinician-administered composite scale. This can enable objective precision measurement of disease severity at scale."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Dementia

Technology and Dementia Preconference. (PubMed, Alzheimers Dement) - "Patients using digital technology autonomously in the home can yield data that matches or exceeds the discriminative power of a traditional composite scale. This can enable objective precision measurement of disease severity at scale."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Pre-Clinical and Clinical Evidence for the treatment of DMG/DIPG using EMulate Therapeutics' Ultra-Low Radio Frequency Magnetic Field Signal Technology (SNO 2024) - "Our research has led to the development of a radio frequency energy (RFE) signal (A1A) that emulates the effects of paclitaxel. Pre-clinical studies demonstrate an effect in slowing down and inhibiting tumor growth.The results of feasibility (Phase I/II) clinical trials testing the EMTx technology for treating recurrent GBM (rGBM) were published in CNS Oncology (CNS Oncol 2023 Pages CNS102, Accession Number: 37462385 DOI: 10.2217/cns-2022-0016)...The company will conduct a study with DIPG patients from both the US and India. Subject to FDA protocol approval, 30-35 patients will be recruited to participate in this pediatric neuro-oncology trial, which will be a best supportive care + single therapy (Hælo®) clinical trial."

Preclinical • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Pediatrics • Solid Tumor

Machine-learning analysis of real-world multimodal data collected autonomously at home detects dementia more precisely than a traditional composite scale (AAIC 2024) - " We present a machine-learning stratification analysis using data from the Cumulus real-world multi-domain neuroassessment platform (Figure 1), in CNS101, a year-long study designed with a consortium of 10 pharma companies... Patients using digital technology autonomously in the home can yield data that matches or exceeds the discriminative power of a traditional composite scale. This can enable objective precision measurement of disease severity at scale."

Clinical • Machine learning • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia

Machine-learning analysis of real-world multimodal data collected autonomously at home detects dementia more precisely than a traditional composite scale (AAIC 2024) - " We present a machine-learning stratification analysis using data from the Cumulus real-world multi-domain neuroassessment platform (Figure 1), in CNS101, a year-long study designed with a consortium of 10 pharma companies... Patients using digital technology autonomously in the home can yield data that matches or exceeds the discriminative power of a traditional composite scale. This can enable objective precision measurement of disease severity at scale."

Clinical • Machine learning • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia

Machine-learning analysis of real-world multimodal data collected autonomously at home detects dementia more precisely than a traditional composite scale (AAIC 2024) - " We present a machine-learning stratification analysis using data from the Cumulus real-world multi-domain neuroassessment platform (Figure 1), in CNS101, a year-long study designed with a consortium of 10 pharma companies... Patients using digital technology autonomously in the home can yield data that matches or exceeds the discriminative power of a traditional composite scale. This can enable objective precision measurement of disease severity at scale."

Clinical • Machine learning • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia